RightFit Trial Directory

Lung Cancer clinical trials in Tucson, AZ

15 recruiting lung cancer studies with a site in Tucson, AZ.

All trials in Tucson, AZ · All Lung Cancer trials

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Gilbert, AZ · Kingman, AZ · Phoenix, AZ · +1147 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Gilbert, AZ · Tucson, AZ · +52 more sites

RecruitingPhase 1NCT03460977

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Sponsor: Pfizer

Tucson, AZ · +42 more sites

RecruitingPhase 3NCT06712355

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Sponsor: BioNTech SE

Tucson, AZ · +35 more sites

RecruitingPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Sponsor: Genmab

Phoenix, AZ · Tucson, AZ · +35 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Gilbert, AZ · Phoenix, AZ · Tucson, AZ · +84 more sites

RecruitingPhase 3NCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Sponsor: AstraZeneca

Tucson, AZ · +62 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Tucson, AZ · +55 more sites

RecruitingPhase 2 / Phase 3NCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Sponsor: Bristol-Myers Squibb

Phoenix, AZ · Tucson, AZ · +42 more sites

RecruitingPhase 2NCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Sponsor: Reunion Neuroscience Inc

Tucson, AZ · +31 more sites

RecruitingPhase 1 / Phase 2NCT05098132

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Sponsor: Synthekine

Tucson, AZ · +32 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Goodyear, AZ · Kingman, AZ · Phoenix, AZ · +1226 more sites

RecruitingNot applicableNCT07216209

The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

Sponsor: University of Arizona

Tucson, AZ

RecruitingPhase 1 / Phase 2NCT05914116

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Sponsor: DualityBio Inc.

Tucson, AZ · +27 more sites

RecruitingPhase 1NCT06069570

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

Sponsor: Kiromic BioPharma Inc.

Tucson, AZ · +4 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.